Sincalide
From Wikipedia, the free encyclopedia
 |
|
|
Sincalide
|
|
| Systematic (IUPAC) name | |
| 3-[[2-[[2-[[2-[[2-[[2-[(2-amino-3-carboxy-propanoyl) amino]-3-(4-sulfooxyphenyl)propanoyl]amino]-4- methylsulfanyl-butanoyl]amino]acetyl]amino]-3- (1H-indol-3-yl)propanoyl]amino]-4-methylsulfanyl- butanoyl]amino]-3-[(1-carbamoyl-2-phenyl-ethyl) carbamoyl]propanoic acid |
|
| Identifiers | |
| CAS number | |
| ATC code | V04 |
| PubChem | |
| Chemical data | |
| Formula | C49H62N10O16S3 |
| Mol. mass | 1143.27 g/mol |
| Synonyms | 1-De(5-oxo-L-proline)-2-de-L-glutamine- 5-L-methioninecaerulein |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
B(US) |
| Legal status | |
| Routes | Intravenous |
Sincalide (INN) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin.
[edit] External links
- Sincalide on NIH.gov
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
